Abstracts tagged "glucocorticoids"

Abstract Number: 1126 • ACR Convergence 2024
The Outcomes of Carpal Tunnel Injections and Carpal Tunnel Surgery
wilmer sibbitt¹, dihowm Fatma¹, N. SUZANNE Emil¹, Maheswari Muruganandam², Roderick A Fields¹, Vangala Adarsh¹, Frank O'Sullivan³, Shuhei Hattori⁴, Frank M Delgado¹ and Krystle Tapia¹, ¹UNM, Albuquerque, NM, ²University of New Mexico, Albuquerque, NM, ³University of New Mexico School of Medicine, Albuquerque, NM, ⁴University of Hawaii, Hawaii
Background/Purpose: arpal tunnel syndrome (CTS) is the most common peripheral neuropathy secondary to chronic median nerve compression at the wrist within the space-limited carpal tunnel…
Abstract Number: 1983 • ACR Convergence 2024
Immune Checkpoint Inhibitor Associated Vasculitis and Polymyalgia Rheumatica: A Systematic Review
Aaron Teel¹, Adrian Grebowicz², Mats Junek³, Stephanie Garner⁴, Tom Appleton⁵ and Faiza Khokhar⁶, ¹London Health Sciences Centre, Sarnia, ON, Canada, ²Western University, London, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵The University of Western Ontario, London, ON, Canada, ⁶McMaster University, St. Joseph's Hamilton, Mississauga, ON, Canada
Background/Purpose: Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy that have been associated with immune-related adverse events (irAEs). These include multiple rheumatic diseases…
Abstract Number: 2435 • ACR Convergence 2024
Attainment of Remission, Use of Immunomodulatory/suppressive Agents and Gradual Dose Tapering May Facilitate Flare-free Withdrawal of Glucocorticoids in Patients with Systemic Lupus Erythematosus
Spyridon Katechis¹, Sofia Pitsigavdaki², Myrto Nikoloudaki², Panagiotis Garantziotis³, Ettore Silvagni⁴, Argyro Repa², Antonio Marangoni⁵, Irini Flouri⁶, Nestor Avgoustidis⁷, Konstantinos Parperis⁸, Marcello Govoni⁵, Prodromos Sidiropoulos⁹, Dimitrios Boumpas¹⁰, Antonios Fanouriakis¹, George Bertsias² and Alessandra Bortoluzzi⁵, ¹Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ²Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece, Heraklion, Greece, ³Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, ⁴Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy, Ferrara, ⁵Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy, Ferrara, Italy, ⁶Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece, Heraklio, Crete, Greece, ⁷University Hospital, Rheumatology and Clinical Immunology,, Heraklion, Greece, ⁸University of Cyprus Medical School, Nicosia, Cyprus, ⁹University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology. Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion, Greece, HERAKLIO, Greece, ¹⁰4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece, Athens, Greece
Background/Purpose: For patients with SLE who are treated with glucocorticoids (GC), discontinuation of the latter is an important goal. However, the clinical conditions under which…
Abstract Number: 1246 • ACR Convergence 2024
Long-Term Outcomes Based on the Sex of the Rheumatologist in a Prospective Cohort of RA Patients Receiving Biological Therapies
Alessandro Giollo¹, Mariangela Salvato², Margherita Zen³ and doria Andrea⁴, ¹Azienda Ospedale Università Padova, Padova, Padua, Italy, ²University of Padua, Padova, Italy, ³University of Padova, Padova, Padua, Italy, ⁴University of Padova, Padova, Italy
Background/Purpose: To explore the influence of the rheumatologist's sex on long-term outcomes in patients with rheumatoid arthritis (RA) undergoing biologic therapy.Methods: This is a prospective,…
Abstract Number: 1989 • ACR Convergence 2024
Higher Early Cumulative Glucocorticoid Exposure Is Associated with Worse Progression-Free Survival in Patients with Immune Checkpoint Inhibitor Inflammatory Arthritis
Minerva Nong¹, Deanna Jannat-Khah², Karmela Kim Chan², Nilasha Ghosh³ and Anne Bass⁴, ¹Hospital for Special Surgery, Tampa, FL, ²Hospital For Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Although immune checkpoint inhibitors (ICI) have transformed cancer treatment, they unleash a range of immune-related adverse events (irAE), including inflammatory arthritis (ICI-IA). Glucocorticoids are…
Abstract Number: 2438 • ACR Convergence 2024
Reduction in Oral Corticosteroid Use During Anifrolumab Therapy: Observations from a Real-world Cohort of Adults with Systemic Lupus Erythematosus
Vasileios Kyttaris¹, Gelareh Atefi², Dan Persons³, Dana Withrow³ and Mawuena Binka⁴, ¹BIDMC, Boston, MA, ²AstraZeneca, Media, PA, ³Trio Health, Louisville, CO, USA, Louisville, ⁴BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE
Background/Purpose: Oral corticosteroids (OCS) are a mainstay in the clinical management of systemic lupus erythematosus (SLE). However, prolonged use may result in systemic side effects.1…
Abstract Number: 1273 • ACR Convergence 2024
An Investigation of Traumatic Events and Mental Health in cSLE
Paris Moaf¹, Ashley Danguecan², Michelle Quilter³, Julie Couture⁴, Daniela Dominguez⁵, Lawrence Ng⁶, Asha Jeyanathan⁷, Reva Schachter⁸, Daphne Korczak⁹, Deborah Levy⁶, Linda Hiraki⁶ and Andrea Knight¹⁰, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ³Whyteman’s Brae Hospital, Kirkcaldy, United Kingdom, ⁴Centre mère-enfant Soleil du CHU de Québec, Québec, Canada, ⁵The Hospital for Sick Children, Toronto, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ⁸Sickkids Toronto, Toronto, ON, Canada, ⁹Hospital for Sick Children, University of toronto, Toronto, ON, Canada, ¹⁰Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with substantial morbidity, particularly in childhood-onset SLE (cSLE). Mental health conditions such as depression and…
Abstract Number: 1991 • ACR Convergence 2024
Initial Corticosteroid Dosing and Effects on Disease Activity, Survival, and Tumor Progression in Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Muhammad Bukhari¹, Ami Shah², Clifton Bingham³, Michelle Jones⁴ and Laura Cappelli¹, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins School of Medicine, Pittsburgh, PA
Background/Purpose: Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) occurs in 3-7% of patients receiving ICI therapy for cancer. ICI-IA is routinely treated with corticosteroids, however, there…
Abstract Number: 2483 • ACR Convergence 2024
Efficacy and Safety of Avacopan over 12 Months in Japanese Patients with MPA/GPA: A Single-center Study
Yusuke Ushio¹, Hiromi Shimada², taichi miyagi³, Koichi Sugihara⁴, Mao Mizusaki⁵, Rina Mino⁵, Hayamasa yamaguchi⁵, Naoto Manabe⁵, Shusaku Nakashima² and Hiroaki Dobashi², ¹Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki, Kita District, Kagawa, Japan, ²Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, kidagun, Japan, ⁴Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa Prefecture, Japan, ⁵Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan
Background/Purpose: Avacopan, an oral C5a receptor inhibitor, was demonstrated to be an alternative to glucocorticoids (GC) in the treatment of microscopic polyangiitis (MPA)/granulomatosis with polyangiitis…
Abstract Number: 0168 • ACR Convergence 2024
Real-world Glucocorticoid Prescription Patterns in Patients with Lupus Nephritis: A Retrospective Study Using a Healthcare Insurance Claims Database
Tatsuya Atsumi¹, Hironari Hanaoka², Nobuo Nishijima³, Kohji Murakami⁴, Mariko Nio³, Tsutomu Urakawa³, Takaaki Fujimura³ and Hiroki Hayashi⁵, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, ⁴Nippon Shinyaku Co., Ltd., Tokyo, Japan, ⁵Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
Background/Purpose: Lupus nephritis (LN) is one of the most frequent organ manifestations of systemic lupus erythematosus (SLE), affecting morbidity and mortality in SLE. LN is…
Abstract Number: 1358 • ACR Convergence 2024
A Step Towards Personalised Medicine – Development and Efficacy of Machine Learning Based Smart-Web Application for Prediction of Steroid Induced Hyperglycemia in Patients with Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases
Manyam Prudhvi Krishna¹, Sandeep Surendran¹, MITHUN CHALAKKARAYIL BHAGAVALDAS², Sundarakrishna Sai³, Sekhar V Easwar¹, Ronith S Kumar³ and Manu Pradeep¹, ¹Amrita Institute of Medical Sciences, Kochi, Kerala, India, ²Amrita Institute of Medical Sciences, ERNAKULAM, Kerala, India, ³Amrita Vishwa Vidyapeetham, Kochi, Kerala, India
Background/Purpose: Steroids play a key role in treating rheumatic diseases due to their anti-inflammatory effects. However, long-term or high-dose use leads to side effects like…
Abstract Number: 2027 • ACR Convergence 2024
Clinical Features and Treatment of Retroperitoneal Fibrosis in a Referral Hospital and Literature Review
Adrián Martín-Gutiérrez¹, Javier Loricera², Fernando Lopez-Gutierrez³ and Ricardo Blanco-Alonso⁴, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Retroperitoneal fibrosis (RPF) is usually idiopathic (iRPF), but may be secondary to drugs, neoplasms, infections, or may be part of an IgG4-related disease. Our…
Abstract Number: 2486 • ACR Convergence 2024
Glucocorticoids May Mitigate the Risk of Avacopan-Induced Liver Dysfunction in ANCA-Associated Vasculitis: Data from a Multicenter Observational Study in Japan
Tomohisa Uchida¹, Shoichi Fukui¹, Naoki Iwamoto¹, Ayaka Umetsu², Momoko Okamoto², Keita Fujikawa², Akinari Mizokami², Takuya Tomokawa³, Kazusato Hara³, Yoshiro Horai³ and Atsushi Kawakami⁴, ¹Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Rheumatology, Japan Community Healthcare Organization (JCHO) Isahaya General Hospital, Isahaya, Japan, ³Department of Rheumatology, Sasebo City General Hospital, Sasebo, Japan, ⁴Nagasaki University, Nagasaki, Japan
Background/Purpose: Avacopan, a C5a receptor inhibitor, has emerged as a novel treatment for ANCA-associated vasculitis (AAV), providing an alternative to glucocorticoids1. Despite its promising potential,…
Abstract Number: 0203 • ACR Convergence 2024
Agreement of Administrative Pharmacy Dispensing with Patient-Reported Use of Oral Glucocorticoids in a Rheumatoid Arthritis Cohort
Beth Wallace¹, Bryant England², Joshua Baker³, Sauer brian⁴, Jorge Rojas⁵, Punyasha Roul⁶, Michael George⁷, Katherine Wysham⁸, Hannah Brubeck⁹, Isaac Smith¹⁰, Liron Caplan¹¹, Paul Monach¹², Gail Kerr¹³, Gary Kunkel¹⁴, Tawnie Braaten¹⁵, Ted Mikuls² and grant Cannon¹⁶, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²University of Nebraska Medical Center, Omaha, NE, ³Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵Seattle VA, Mexico, Mexico, ⁶UNMC, Omaha, NE, ⁷University of Pennsylvania, Philadelphia, PA, ⁸VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁹VA Puget Sound Health Care System, Seattle, WA, ¹⁰Duke Department of Medicine; VA Durham Healthcare System, Durham, NC, ¹¹Univ of Colorado School of Medicine/Rocky Mtn Regional Veterans Affairs Medical Center, Aurora, CO, ¹²VA Boston Healthcare System, Boston, MA, ¹³Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁴University of Utah/VA Salt Lake City Health Care, Salt Lake City, UT, ¹⁵UNIVERSITY OF UTAH, Salt Lake City, UT, ¹⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Administrative claims are often used to evaluate oral glucocorticoid (GC) use in RA for clinical and research purposes, despite limited evidence to support their…
Abstract Number: 1483 • ACR Convergence 2024
Real World Data on Infections from the Indian SLE Inception Cohort for Research (INSPIRE): Spectrum and Risk Factors
SAUMYA TRIPATHY¹, DEBASISH PANDIT², Sarit Pattanaik³, Liza Rajasekhar⁴, VINEETA SHOBHA⁵, Chengappa Kavadichanda⁶, Ashish J Mathew⁷, Parasar Ghosh⁸, Ranjan Gupta⁹, Manish Rathi¹⁰, AVINASH JAIN¹¹, MANOJ PARIDA¹², Bidyut Das¹³ and Amita Aggarwal¹⁴, ¹SCB Medical College, Cuttack, Odisha, India, Cuttack, Orissa, India, ²SJM MCH, Puri, Puri, Orissa, India, ³SCB Medical College and Hospital, Cuttack, Odisha, Cuttack, Orissa, India, ⁴Nizam's Institute of Medical Sciences, Madhapur, Andhra Pradesh, India, ⁵ST JOHN'S MEDICAL COLLEGE, BENGALURU, Karnataka, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁷Christian Medical College, Vellore, Tamil Nadu, India, ⁸Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁹All India Institute of Medical Sciences, New Delhi, Delhi, India, ¹⁰Postgraduate Institute of Medical Education & Research, Chandigarh, Chandigarh, India, ¹¹SMS MCH, JAIPUR, JAIPUR, Rajasthan, India, ¹²SCB MEDICAL COLLEGE, CUTTACK, Cuttack, Orissa, India, ¹³SCB Medical College, Cuttack, Orissa, India, ¹⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Infections in SLE are a major cause of morbidity and mortality. The susceptibility to infections in SLE is multifactorial. Immune dysregulation, immunosuppressive drug use and…

1
2
3
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].